Surveillance of Transmitted Drug-Resistant HIV Among Young Pregnant Women in Ouagadougou, Burkina Faso | Zendy

A. Somda | Zendy; Lassana Sangaré | Zendy; Monique Soro | Zendy; Suzanne Yameogo | Zendy; Betty Jean | Zendy; F. Bigirimana | Zendy; Silvia Bertagnolio | Zendy; Martine Peeters | Zendy; Fatima Mouacha | Zendy; Argelis Rivera | Zendy; Michael R. Jordan | Zendy; Maïmouna Sanou | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Surveillance of Transmitted Drug-Resistant HIV Among Young Pregnant Women in Ouagadougou, Burkina Faso

Author(s) -

A. Somda,

Lassana Sangaré,

Monique Soro,

Suzanne Yameogo,

Betty Jean,

F. Bigirimana,

Silvia Bertagnolio,

Martine Peeters,

Fatima Mouacha,

Argelis Rivera,

Michael R. Jordan,

Maïmouna Sanou

Publication year - 2012

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir988

Subject(s) - medicine , antiretroviral therapy , human immunodeficiency virus (hiv) , drug resistance , pregnancy , obstetrics , environmental health , virology , viral load , genetics , microbiology and biotechnology , biology

Burkina Faso began rapid antiretroviral therapy (ART) scale-up in 2003 and by December 2009, 26,448 individuals were on treatment. With rapid scale-up of ART, some degree of human immunodeficiency virus transmitted drug resistance (TDR) is inevitable. Following World Health Organization methods, between June 2008 and July 2009, Burkina Faso assessed TDR in primigravid pregnant women aged <25 years attending antenatal care clinics in Ouagadougou, Burkina Faso. TDR was classified as moderate (5%-15%) for both nucleoside reverse-transcriptase inhibitors and nonnucleoside reverse-transcriptase inhibitors. The observed moderate TDR in Ouagadougou is a cause for concern and calls for closer monitoring of Burkina Faso's ART program.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research